PolyPid Ltd. (PYPD) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Polypeed's first quarter 2026 earnings conference call. At this time, participants are in a listen-only mode. As a reminder, this call is recorded and I would now like to introduce your host for today's conference, Yehuda Libra from ARX Investor Relations. Mr. Libra, you may begin. Thank you, Operator, and thank you all for joining PolyPID's first quarter 2026 earnings conference call. Joining me on the call today will be Dikla Chachkis-Axelbrad, Chief Executive Officer of PolyPID, Johnny Misalawin, PolyPID's Chief Financial Officer, and Ori Warshavsky, Chief Operating Officer, U.S. of PolyPID. Earlier today, PolyPID released its financial results for the three months ended March 31st, 2026. A copy of the press release is available on the Investors section of the company's website at www.polypid.com. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws. For example, management is making forward-looking statements when discussing the company's regulatory strategy, including the expected completion of the rolling new drug application, or NDA, submission for DPLEX-100. Management may also discuss the company's planned engagements with the European Medicines Agency, or EMA, including meetings with the repertoire or co-repertoire regarding the planned marketing authorization application, or MAA, and the anticipated timing thereof. In addition, management may discuss the company's ongoing U.S. commercial strategic partnership discussions, its belief that those discussions are in late stages, and expected launch plans and timing. Other forward-looking statements may relate to the potential clinical and economic value proposition of V-Plex 100, the company's prepar...